Full Text View
Tabular View
No Study Results Posted
Related Studies
Dovitinib in Neuroendocrine Tumors
This study is currently recruiting participants.
Verified February 2013 by Abramson Cancer Center of the University of Pennsylvania
Study NCT01635907   Information provided by Abramson Cancer Center of the University of Pennsylvania

First Received on July 5, 2012.   Last Updated on February 26, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Metastatic Paraganglioma
Recurrent Paraganglioma
Recurrent Pheochromocytoma
Unresectable Paraganglioma
Unresectable Pheochromocytoma
Additional conditions recognized in this trial
Neuroendocrine Tumors
Paraganglioma
Pheochromocytoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Interventions listed in this trial
Dovitinib
Sponsors listed in this trial
Abramson Cancer Center of the University of Pennsylvania
Stephen Keefe,MD, Principal Investigator
Beth Fox, MD , Sponsor Investigator


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services